Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Under Scrutiny: Congress Presses Agency On Antidepressants, Plan B

Executive Summary

Congress is asking FDA to document its actions in two high-profile agency decisions

You may also be interested in...



FDA Drug Safety Office Is “Separate, But Unequal,” Senate Committee Says

A Senate committee investigation into FDA's handling of pediatric suicidality concerns with antidepressant drugs is focusing on the "unequal" status of the Office of Drug Safety and the Office of New Drugs

FDA Drug Safety Office Is “Separate, But Unequal,” Senate Committee Says

A Senate committee investigation into FDA's handling of pediatric suicidality concerns with antidepressant drugs is focusing on the "unequal" status of the Office of Drug Safety and the Office of New Drugs

FDA Handling Of Antidepressant Inquiry “Troubles” Senate Investigators

The Senate Finance Committee is asking for contact information for former employees of FDA's Office of Drug Safety in its continuing investigation into the agency's handling of information on a possible link between antidepressants and suicide

Related Content

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel